Specific side effects of long-term imipramine management of panic disorder.

Abstract:

:In a recent study, the authors suggested that tachycardia, dry mouth, and sweating continued to burden patients with panic disorder with agoraphobia who have shown marked and stable response to 6 months of imipramine treatment at the fixed, weight-adjusted dose of 2.25 mg/kg/day. Although sexual dysfunction and weight gain were not a significant burden in that study, they are important problems in long-term treatment with antidepressant drugs. In the present study, in the context of a randomized, double-blind, placebo-controlled, 1-year discontinuation and maintenance study of 53 patients with panic disorder with agoraphobia who respond to imipramine, the authors examine the extent and the specificity of these five side effects of imipramine maintenance using data at pretreatment, at the end of 24 weeks of open imipramine treatment (or month 0 of randomization), and at months 2, 4, 6, 8, 10, and 12 of randomized treatment. Hierarchical linear modeling and repeated measures of analyses of variance in subsamples of completers confirmed that dry mouth, sweating, and increased heart rate constitute a significant and specific enduring burden of imipramine maintenance treatment. The data also revealed that weight gain is a significant and specific side effect of 1-year imipramine maintenance treatment; however, the likelihood of reporting sexual dysfunction decreased over time, with no difference between the placebo and imipramine maintenance conditions. The results are discussed in the context of previous studies of imipramine side effects in the management of depression and the available literature of sexual and weight side effects of antidepressant medications in the treatment of anxiety disorders.

journal_name

J Clin Psychopharmacol

authors

Mavissakalian M,Perel J,Guo S

doi

10.1097/00004714-200204000-00008

subject

Has Abstract

pub_date

2002-04-01 00:00:00

pages

155-61

issue

2

eissn

0271-0749

issn

1533-712X

journal_volume

22

pub_type

临床试验,杂志文章,随机对照试验
  • Nifedipine in the treatment of tardive dyskinesia.

    abstract::There have been several case reports of improvement in tardive dyskinesia (TD) after treatment with calcium-blocking agents. We have conducted prior single-blind (rater-blind) studies of verapamil and diltiazem and found a statistically significant improvement in TD with verapamil, and a small improvement that did not...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-199010060-00006

    authors: Duncan E,Adler L,Angrist B,Rotrosen J

    更新日期:1990-12-01 00:00:00

  • WITHDRAWN:A Validation Study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome.

    abstract::Ahead of Print article withdrawn by publisher. ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e31829ab413

    authors: Gurrera RJ,Velamoor V,Cernovsky ZZ

    更新日期:2013-08-22 00:00:00

  • Risperidone for the treatment of stuttering.

    abstract::A randomized, double-blind, placebo-controlled study was conducted to assess the efficacy of risperidone in the treatment of developmental stuttering in 16 adults. Eight subjects received placebo and eight received risperidone at 0.5 mg once daily at night, increased to a maximum of 2 mg/day. After 6 weeks of treatmen...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200008000-00013

    authors: Maguire GA,Riley GD,Franklin DL,Gottschalk LA

    更新日期:2000-08-01 00:00:00

  • Inhibition of CYP2D6 activity by bupropion.

    abstract::The purpose of this study was to assess the effect of bupropion on cytochrome P450 2D6 (CYP2D6) activity. Twenty-one subjects completed this repeated-measures study in which dextromethorphan (30-mg oral dose) was administered to smokers at baseline and after 17 days of treatment with either bupropion sustained-release...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000162805.46453.e3

    authors: Kotlyar M,Brauer LH,Tracy TS,Hatsukami DK,Harris J,Bronars CA,Adson DE

    更新日期:2005-06-01 00:00:00

  • Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder.

    abstract::The aim of this post-hoc analysis was to determine whether early symptom improvement with extended release quetiapine (quetiapine XR) may predict treatment outcome in patients with major depressive disorder. Data were from 6, double-blind, placebo-controlled studies of quetiapine XR (2 fixed-dose and 2 flexible-dose m...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/JCP.0000000000000416

    authors: McIntyre RS,Gorwood P,Thase ME,Liss C,Desai D,Chen J,Bauer M

    更新日期:2015-12-01 00:00:00

  • Aripiprazole in schizophrenia with cocaine dependence: a pilot study.

    abstract::The debilitation of schizophrenia (SCHZ) worsens markedly with comorbid cocaine dependence (CD) and alcohol abuse. To date, no medications have conclusively demonstrated effects against both SCHZ and CD (SCHZ + CD) simultaneously. Because of its dopamine-modulating properties, we hypothesized that aripiprazole would a...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.jcp.0000169419.38899.5b

    authors: Beresford TP,Clapp L,Martin B,Wiberg JL,Alfers J,Beresford HF

    更新日期:2005-08-01 00:00:00

  • Plasma haloperidol and clinical response: a role for reduced haloperidol in antipsychotic activity?

    abstract::Seventeen hospitalized psychotic patients were treated with a fixed oral dose of haloperidol, 5 mg twice daily for 28 days. Most were chronic schizophrenics with an acute exacerbation of their illness. All patients also received benztropine 3 mg twice daily during the last 11 days of the study, regardless of the prese...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Shostak M,Perel JM,Stiller RL,Wyman W,Curran S

    更新日期:1987-12-01 00:00:00

  • An Open Trial of Iloperidone for Mixed Episodes in Bipolar Disorder.

    abstract:BACKGROUND:Mixed mood states in bipolar disorder are difficult to treat and when present indicate worse illness trajectories. Several medications are US Food and Drug Administration approved to treat mixed episodes; however, the clinical trials have been short term and rarely reported depression response. METHODS:We c...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/JCP.0000000000000764

    authors: Singh V,Arnold JG,Prihoda TJ,Martinez M,Bowden CL

    更新日期:2017-10-01 00:00:00

  • Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder.

    abstract::Tolcapone is a catechol-O-methyltransferase (COMT) inhibitor that has shown efficacy in the treatment of Parkinson's disease. The authors undertook the first study on the efficacy of this COMT inhibitor in the treatment of major depressive disorder (MDD). The authors also wanted to assess the effects of tolcapone on t...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-199908000-00008

    authors: Fava M,Rosenbaum JF,Kolsky AR,Alpert JE,Nierenberg AA,Spillmann M,Moore C,Renshaw P,Bottiglieri T,Moroz G,Magni G

    更新日期:1999-08-01 00:00:00

  • Persistence of fluphenazine in plasma after decanoate withdrawal.

    abstract::We discontinued fluphenazine decanoate using a double-blind, crossover random order design, in 12 recent onset clinically stable schizophrenics who had been given fluphenazine decanoate 12.5 mg intramuscularly every 2 weeks for at least 1 year prior to drug withdrawal. Each condition (drug or placebo) lasted 12 weeks....

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Gitlin MJ,Midha KK,Fogelson D,Nuechterlein K

    更新日期:1988-02-01 00:00:00

  • Pharmacologic induction of cholinergic system up-regulation and supersensitivity in affective disorders research.

    abstract::Phenomenological, physiological, biochemical, and receptor binding measures are useful as dependent variables in affective disorders research. Abnormalities of these measures can result from up-regulation and supersensitivity of cholinergic systems and disturbances of cholinergic-monoaminergic interaction. These devia...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Dilsaver SC

    更新日期:1986-04-01 00:00:00

  • US psychiatric residents' treatment of patients with bipolar disorder.

    abstract::We aimed to evaluate the practice patterns of US postgraduate year (PGY) levels 3 and 4 psychiatric residents in the treatment of patients with bipolar disorder (BD) types I and II. We also aimed to determine whether confidence in prescribing mood stabilizers is associated with residents' practice patterns. The reside...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e31824857ad

    authors: Rakofsky JJ,Dunlop BW

    更新日期:2012-04-01 00:00:00

  • Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression.

    abstract:OBJECTIVE:Medication algorithms have been proposed as effective means to offer optimal treatment and improved outcome for patients with severe mental illness. This single-center prospective study compared the efficacy and effects on treatment prescriptions of an algorithm-guided treatment regimen with treatment as usua...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0b013e3181ac4839

    authors: Bauer M,Pfennig A,Linden M,Smolka MN,Neu P,Adli M

    更新日期:2009-08-01 00:00:00

  • Psychological strategies for discontinuing benzodiazepine treatment.

    abstract::Successful discontinuation of therapeutic drugs requires patients to negotiate two potentially difficult phases. First, they must complete the drug discontinuation procedure itself, which may entail coping with rebound and withdrawal symptoms as well as anxiety due to stopping a treatment on which they depend psycholo...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004714-199912002-00004

    authors: Spiegel DA

    更新日期:1999-12-01 00:00:00

  • Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9-year naturalistic follow-up study.

    abstract::Twenty-eight patients with a DSM-III diagnosis of agoraphobia with panic attacks who completed a 4-month combined drug and behavioral treatment program and who were then discharged on imipramine were interviewed 1 to 5 years after being discharged. At the time of follow-up, half of the patients were medication free, e...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Nagy LM,Krystal JH,Charney DS,Merikangas KR,Woods SW

    更新日期:1993-02-01 00:00:00

  • Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers.

    abstract::The neurotransmitter dopamine is integrally involved in the rewarding effects of drugs, and it has also been thought to mediate impulsive behaviors in animal models. Most of the studies of drug effects on impulsive behaviors in humans have involved drugs with complex actions on different transmitter systems and differ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/jcp.0b013e3181602fab

    authors: Hamidovic A,Kang UJ,de Wit H

    更新日期:2008-02-01 00:00:00

  • The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study.

    abstract::Trichotillomania (TTM) is characterized by repetitive hair pulling resulting in hair loss. Data on the pharmacological treatment of TTM are limited. This study examined the opioid antagonist, naltrexone, in adults with TTM who had urges to pull their hair. Fifty-one individuals with TTM were randomized to naltrexone o...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0000000000000037

    authors: Grant JE,Odlaug BL,Schreiber LR,Kim SW

    更新日期:2014-02-01 00:00:00

  • Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial.

    abstract:BACKGROUND:Combination antipsychotics (CAs) are prescribed in schizophrenia despite limited evidence of efficacy. To explore the effect of switching from CA to monotherapy, we performed an exploratory analysis of the PROACTIVE (Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared with Injectables: Evaluati...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000766

    authors: Foster A,Buckley P,Lauriello J,Looney S,Schooler N

    更新日期:2017-10-01 00:00:00

  • Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.

    abstract::Switching antipsychotic regimen to agents with low weight gain potential has been suggested in patients who gain excessive weight on their antipsychotic therapy. In an open-label pilot study, we evaluated the metabolic and psychiatric efficacy of switching to aripiprazole in 15 (9 men, 6 women) outpatients with schizo...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e3180a9076c

    authors: Kim SH,Ivanova O,Abbasi FA,Lamendola CA,Reaven GM,Glick ID

    更新日期:2007-08-01 00:00:00

  • Molindone hydrochloride: a review of laboratory and clinical findings.

    abstract::Molindone hydrochloride, a dihydroindolone neuroleptic, is structurally distinct from other classes of neuroleptics. Molindone exhibits many similarities to other neuroleptics, including dopamine receptor blockade, antipsychotic efficacy, and extrapyramidal side effects. Despite these similarities, molindone also has ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Owen RR Jr,Cole JO

    更新日期:1989-08-01 00:00:00

  • Open-label pilot study of modafinil for methamphetamine dependence.

    abstract::Methamphetamine has become a major public health issue globally, particularly in the United States. Despite this, no effective pharmacotherapy for methamphetamine abuse has been developed to date. This 6-week, open-label pilot clinical trial examined the safety and tolerability of modafinil up to 400 mg/d in 8 methamp...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/JCP.0b013e3181b591e0

    authors: McGaugh J,Mancino MJ,Feldman Z,Chopra MP,Gentry WB,Cargile C,Oliveto A

    更新日期:2009-10-01 00:00:00

  • A double-blind comparison of moclobemide and thioridazine versus moclobemide and placebo in the treatment of refractory, severe depression.

    abstract::In a multicenter study of 78 severely depressed inpatients (44 women and 34 men; age range, 23 to 70 years), the efficacy, onset of efficacy, and tolerability of the reversible monoamine oxidase-A inhibitor moclobemide (450 mg/day) in combination with thioridazine (100 mg/day) were compared with those of moclobemide (...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-199508001-00008

    authors: Stabl M,Kasas A,Blajev B,Bajetta G,Zöchling R,Holsboer-Trachsler E,Realini R,Schäublin-Loidl M

    更新日期:1995-08-01 00:00:00

  • Double-blind clinical trial of sertraline treatment for alcohol dependence.

    abstract::Clinical studies that have evaluated serotonergic medications to reduce alcohol consumption have yielded conflicting results. These studies primarily treated patients with alcohol dependence, excluding those with a current depressive disorder, in an effort to differentiate any medication effects directly on drinking f...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200104000-00005

    authors: Pettinati HM,Volpicelli JR,Luck G,Kranzler HR,Rukstalis MR,Cnaan A

    更新日期:2001-04-01 00:00:00

  • Antipsychotic Use and the Risk of Initiating Medication for Benign Prostate Hyperplasia in Persons With Alzheimer Disease: A Matched Cohort Study.

    abstract:BACKGROUND:Antipsychotics (APs) are known to exacerbate symptoms of benign prostate hyperplasia (BPH) and may even cause urinary retention. The anticholinergic effects of APs and their dopamine D2- and α-receptor blockade may lead to voiding dysfunction of BPH patients. The objective of our study was to investigate whe...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000928

    authors: Orsel K,Taipale H,Raatikainen S,Lampela P,Tolppanen AM,Koponen M,Tanskanen A,Tiihonen J,Gardarsdottir H,Hartikainen S

    更新日期:2018-10-01 00:00:00

  • Effects of age and sex on olanzapine plasma concentrations.

    abstract::Age and sex may influence both efficacy and side effects of second-generation antipsychotics. Women and elderly patients tend to have a higher prevalence for several side effects. Higher plasma levels in these groups of patients may be one reason. We studied the hypothesis that steady-state olanzapine plasma concentra...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.jcp.0000185427.08268.db

    authors: Weiss U,Marksteiner J,Kemmler G,Saria A,Aichhorn W

    更新日期:2005-12-01 00:00:00

  • Alprazolam treatment of postcoronary bypass anxiety and depression.

    abstract::The effectiveness of alprazolam in treating symptoms of anxiety and depression in 60 patients undergoing coronary bypass surgery was assessed in a double-blind, placebo-controlled study. The results indicate that alprazolam treatment for anxiety following coronary bypass surgery, particularly symptoms occurring in the...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Freeman AM 3rd,Fleece L,Folks DG,Sokol RS,Hall KR,Pacifico AD,McGiffin DC,Kirklin JK,Zorn GL,Karp RB

    更新日期:1986-02-01 00:00:00

  • Rhabdomyolysis complicating rapid intramuscular neuroleptization.

    abstract::A case of rhabdomyolysis is described, with onset following three intramuscular injections of loxapine and one injection of benztropine over a 7-hour period. The possible additive effects of intramuscular drug administration and psychotic episode-associated increased muscle membrane permeability are discussed. Because...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Thase ME,Shostak M

    更新日期:1984-02-01 00:00:00

  • Mianserin pharmacokinetics and behavior in hyperkinetic children.

    abstract::The present study was conducted to derive pediatric mianserin pharmacokinetic parameters, which were compared to those from healthy young adults, and to obtain preliminary information regarding the utility of mianserin for the management of hyperkinesis in children. The sample consisted of six prepubescent children wi...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Winsberg BG,Camp-Bruno JA,Vink J,Timmer CJ,Sverd J

    更新日期:1987-06-01 00:00:00

  • The Utility of Low-Dose Aripiprazole for the Treatment of Bipolar II and Bipolar NOS Depression.

    abstract:BACKGROUND:Despite initial reports of efficacy in bipolar depression, multicenter trials did not show aripiprazole to be better than placebo, possibly because the doses used were too high, leading to lower efficacy and high dropout rates. This study evaluated the effects of low-dose aripiprazole. Extensive clinical exp...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000636

    authors: Kelly T,Lieberman DZ

    更新日期:2017-02-01 00:00:00

  • Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks.

    abstract::Fifty-five patients completed a 5-week double-blind study comparing alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. There was no concomitant behavioral treatment. Patient and therapist rating scales included Sheehan's Panic and Anxiety Attack Scales, the Mark...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Munjack DJ,Crocker B,Cabe D,Brown R,Usigli R,Zulueta A,McManus M,McDowell D,Palmer R,Leonard M

    更新日期:1989-02-01 00:00:00